COVID-19 vaccine is a game changer for economies, markets, and investors


We can look past the economic shock and focus more confidently on the recovery. Do investors need to rethink positioning?


The Pfizer/BioNTech COVID-19 vaccine announcement on Nov. 9 was received by equity markets with enthusiasm, with the S&P 500 rallying 1.2 percent on the day, and the MSCI World Index reaching a new all-time high the day after. The results markedly surpassed general expectations, especially in terms of the vaccine’s efficacy in preventing symptoms, and some market participants seemed surprised by the timing of its availability. The vaccine is likely to be the first one to receive regulatory approval in the U.S. and Europe, which could happen within weeks.

The vaccine’s efficacy rate of more than 90 percent, far exceeding the U.S. Food and Drug Administration’s (FDA) 50 percent hurdle rate, is remarkably high for a first-generation vaccine. This could mean other vaccines using a similar technology are likely to be successful as well.

Some questions remain, including how safe the vaccine is, though this data should also be available within weeks. With time, we will find out how long the vaccine protection lasts and how efficient it is when used on the elderly, as cohorts are added to the trial.

Enthusiasm for the Pfizer/BioNTech vaccine is tempered by logistical challenges. It requires two doses to be administered three weeks apart. It also needs to be stored in dry ice to ensure a temperature of minus 70 degrees Celsius (-94 F) or below—a challenge for governments considering rolling it out, particularly for developing countries and those in temperate regions.

Once safety data is released, emergency use filing can be done in the U.S. and Europe. After receiving the full efficacy data in December, the FDA can approve the drug. Pfizer/BioNTech expects that 50 million doses can be available by year-end and 1.3 billion doses next year (i.e., 750 million vaccinated). For context, the EU has ordered 300 million doses, the U.S. 100 million, and the UK 30 million.

The possibility of vaccines taming the pandemic is becoming more tangible. Data for two other vaccines are due before the end of the year. The vaccine being developed by AstraZeneca and Oxford University is possibly the most eagerly anticipated. Based on a different technology, only one dose is required, and it wouldn’t need to be kept below freezing temperatures, suggesting it would be more scalable than Pfizer/BioNTech’s. Moreover, it is reportedly already known to be effective for the elderly. We should also know the results of the Moderna vaccine trial by year-end and the results of four others will likely come in sometime in the first half of next year. Should most of these be successful, the global vaccination rollout could make important inroads next year.

Good for the economy

To be sure, the manufacturing capacity and the distribution of the vaccine will not be in place to save the winter in the Northern Hemisphere. Social distancing and lockdown measures will likely stay in place for now, capping economic growth in the economically important Q4 2020 and possibly in Q1 2021. But the Pfizer/BioNTech data brings forward the possibility of a better outlook for economic growth in 2021 for several reasons, and as such, it is undeniably good news.

The availability of a vaccine and the success of its technology likely reduces the risk of a potential third wave in autumn 2021. Knowing there is an end to the crisis in sight, some governments could opt to give more generous fiscal relief than would have otherwise been the case. Our national research correspondent thinks a U.S. COVID-19 stimulus package of $1 trillion is more likely than one of $500 billion. A vaccine also helps investors to look through the COVID-19 valley and focus more confidently on the recovery and the post-pandemic world.

The vaccine announcement brought on abrupt risk-on moves in financial markets that day. The S&P 500 closed up 1.2 percent, a performance that came on top of post-election gains which had been the highest in history.

Sharpest market reversal since 2009
Daily price change in the Bloomberg US Pure Momentum Portfolio Total Return Index
Chart of daily price change (percentage) in the Bloomberg US Pure Momentum Portfolio             Total Return Index from March 2009 through Nov. 10, 2020.
Positive COVID-19 vaccine results announced

Source – Bloomberg; daily data through 11/10/20

The S&P 500’s move camouflages an aggressive rotation in equity markets. Momentum strategies, in which investors buy securities when their prices have been rising and sell those when they have been declining, had their worst performance since 2009. The FAANGs (Facebook, Amazon, Apple, Netflix, and Google parent Alphabet), which have led market gains since March, also retreated abruptly. These technology companies’ business models have thrived in the COVID-19 era, with their stocks being widely perceived by market participants as defensive investments in these difficult times. Globally, megacaps underperformed riskier small caps. Struggling Financials and Energy stocks roared upwards. Meanwhile, the oversold FTSE All-Share Index, a broad index of UK stocks, closed up approximately five percent, a rarely seen showing and its second-best performance since the 2016 Brexit referendum.

Other traditional growth indicators also pointed to an improvement in the economic outlook: the U.S. yield curve steepened, with the yield on the 10-year Treasury note increasing to 0.95 percent from 0.80 percent prior to the vaccine announcement. Profit-takers brought gold prices down to $1,855/oz, perhaps a sign of a safer environment.

A flash in the pan?

For investors, the question is whether these aggressive one-day moves herald a broader, more sustained rotation towards cyclical positions. To be fair, they were probably also a function of crowded positions, i.e., investors all chasing similar themes and being heavy in certain sectors (such as the FAANG group with their resilient business models for the current environment) while avoiding others (like the Energy sector due to the sharp fall in oil prices and banks due to ultralow interest rates). The aggressive market rotation also facilitated a record valuation differential between growth and value stocks.

A general and longer-lasting rotation towards reflationary positioning, or economically-sensitive stocks, would require inflation expectations to continue their ascent and Treasury yields to extend their moves upward.

For now, we believe it’s reasonable to expect a period of consolidation for equities following the sharp gains since the U.S. elections and vaccine news. Moreover, the global economy is not out of the woods yet, and investors may start to ponder the logistical challenges of rolling out vaccines globally.

Investors should use this time to consider their portfolios’ exposure to cyclicality, or economically-sensitive stocks. The possibility of viable vaccines should enable investors to look through the crisis and assess companies that were most affected by COVID-19 on the basis of normalised earnings. Many of these companies’ stocks will appear undervalued, in our view. We recommend adding some exposure to cyclicals and value stocks to take advantage of the likely improvement in economic conditions that COVID-19 vaccines could bring.

Non-U.S. Analyst Disclosure: Frédérique Carrier, an employee of RBC Wealth Management USA’s foreign affiliate RBC Europe Limited, contributed to the preparation of this publication. This individual is not registered with or qualified as a research analyst with the U.S. Financial Industry Regulatory Authority (“FINRA”) and, since they are not associated persons of RBC Wealth Management, they may not be subject to FINRA Rule 2241 governing communications with subject companies, the making of public appearances, and the trading of securities in accounts held by research analysts.

This publication has been issued by Royal Bank of Canada on behalf of certain RBC ® companies that form part of the international network of RBC Wealth Management. You should carefully read any risk warnings or regulatory disclosures in this publication or in any other literature accompanying this publication or transmitted to you by Royal Bank of Canada, its affiliates or subsidiaries.

The information contained in this report has been compiled by Royal Bank of Canada and/or its affiliates from sources believed to be reliable, but no representation or warranty, express or implied is made to its accuracy, completeness or correctness. All opinions and estimates contained in this report are judgments as of the date of this report, are subject to change without notice and are provided in good faith but without legal responsibility. This report is not an offer to sell or a solicitation of an offer to buy any securities. Past performance is not a guide to future performance, future returns are not guaranteed, and a loss of original capital may occur. Every province in Canada, state in the U.S. and most countries throughout the world have their own laws regulating the types of securities and other investment products which may be offered to their residents, as well as the process for doing so. As a result, any securities discussed in this report may not be eligible for sale in some jurisdictions. This report is not, and under no circumstances should be construed as, a solicitation to act as a securities broker or dealer in any jurisdiction by any person or company that is not legally permitted to carry on the business of a securities broker or dealer in that jurisdiction. Nothing in this report constitutes legal, accounting or tax advice or individually tailored investment advice.

This material is prepared for general circulation to clients, including clients who are affiliates of Royal Bank of Canada, and does not have regard to the particular circumstances or needs of any specific person who may read it. The investments or services contained in this report may not be suitable for you and it is recommended that you consult an independent investment advisor if you are in doubt about the suitability of such investments or services. To the full extent permitted by law neither Royal Bank of Canada nor any of its affiliates, nor any other person, accepts any liability whatsoever for any direct or consequential loss arising from any use of this report or the information contained herein. No matter contained in this document may be reproduced or copied by any means without the prior consent of Royal Bank of Canada.

Clients of United Kingdom companies may be entitled to compensation from the UK Financial Services Compensation Scheme if any of these entities cannot meet its obligations. This depends on the type of business and the circumstances of the claim. Most types of investment business are covered for up to a total of £85,000. The Channel Island subsidiaries are not covered by the UK Financial Services Compensation Scheme; the offices of Royal Bank of Canada (Channel Islands) Limited in Guernsey and Jersey are covered by the respective compensation schemes in these jurisdictions for deposit taking business only.

Let’s connect

We want to talk about your financial future.

Related articles

Life after sports requires a new game plan

Analysis 5 minute read
- Life after sports requires a new game plan

Adapt or risk losing the next generation of HNWIs

Analysis 4 minute read
- Adapt or risk losing the next generation of HNWIs

How long will the economic recovery take?

Analysis 5 minute read
- How long will the economic recovery take?